Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Kato ET, et al. Among authors: goto s. Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18. Circulation. 2019. PMID: 30882238 Clinical Trial.
Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial.
Wiviott SD, Flather MD, O'Donoghue ML, Goto S, Fitzgerald DJ, Cura F, Aylward P, Guetta V, Dudek D, Contant CF, Angiolillo DJ, Bhatt DL; LANCELOT-CAD Investigators. Wiviott SD, et al. Among authors: goto s. Circulation. 2011 May 3;123(17):1854-63. doi: 10.1161/CIRCULATIONAHA.110.001404. Epub 2011 Apr 18. Circulation. 2011. PMID: 21502571 Clinical Trial.
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial.
O'Donoghue ML, Bhatt DL, Wiviott SD, Goodman SG, Fitzgerald DJ, Angiolillo DJ, Goto S, Montalescot G, Zeymer U, Aylward PE, Guetta V, Dudek D, Ziecina R, Contant CF, Flather MD; LANCELOT-ACS Investigators. O'Donoghue ML, et al. Among authors: goto s. Circulation. 2011 May 3;123(17):1843-53. doi: 10.1161/CIRCULATIONAHA.110.000786. Epub 2011 Apr 18. Circulation. 2011. PMID: 21502577 Clinical Trial.
One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE).-.
Goto S, Ikeda Y, Shimada K, Uchiyama S, Origasa H, Kobayashi H; J-TRACE Investigators. Goto S, et al. Circ J. 2011;75(11):2598-604. doi: 10.1253/circj.cj-11-0378. Epub 2011 Aug 20. Circ J. 2011. PMID: 21857143 Free article. Clinical Trial.
Rivaroxaban in patients with a recent acute coronary syndrome.
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Mega JL, et al. Among authors: goto s. N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13. N Engl J Med. 2012. PMID: 22077192 Free article. Clinical Trial.
Vorapaxar in the secondary prevention of atherothrombotic events.
Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators. Morrow DA, et al. N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24. N Engl J Med. 2012. PMID: 22443427 Free article. Clinical Trial.
Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.
Roussel R, Hadjadj S, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Tubach F, Marre M, Porath A, Krempf M, Bhatt DL, Steg PG. Roussel R, et al. Among authors: goto s. Int J Cardiol. 2013 Aug 20;167(4):1380-4. doi: 10.1016/j.ijcard.2012.04.019. Epub 2012 May 4. Int J Cardiol. 2013. PMID: 22560911
Living alone and cardiovascular risk in outpatients at risk of or with atherothrombosis.
Udell JA, Steg PG, Scirica BM, Smith SC Jr, Ohman EM, Eagle KA, Goto S, Cho JI, Bhatt DL; REduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Udell JA, et al. Among authors: goto s. Arch Intern Med. 2012 Jul 23;172(14):1086-95. doi: 10.1001/archinternmed.2012.2782. Arch Intern Med. 2012. PMID: 22711020
An international model to predict recurrent cardiovascular disease.
Wilson PW, D'Agostino R Sr, Bhatt DL, Eagle K, Pencina MJ, Smith SC, Alberts MJ, Dallongeville J, Goto S, Hirsch AT, Liau CS, Ohman EM, Röther J, Reid C, Mas JL, Steg PG; REACH Registry. Wilson PW, et al. Among authors: goto s. Am J Med. 2012 Jul;125(7):695-703.e1. doi: 10.1016/j.amjmed.2012.01.014. Am J Med. 2012. PMID: 22727237
3,648 results